Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felcorekibart dose-finding study in adults with uncontrolled asthma
2024-518321-15-00Phase 2Authorised
- Sponsor
- GSK
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing Felcorekibart dose arm(s) with Placebo (2 arms). Primary endpoint: FeNO over 26 weeks. Planned start May 2025; status: authorised.
02
Drugs
felcorekibart
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-518321-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518321-15-00.